Target intelligence / Profile preview

Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1)

Target
UBE2Q1
Molecular classification
Enzyme, Ubiquitin-conjugating enzyme (E2 family)
01

Overview

Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1) is a member of the E2 ubiquitin-conjugating enzyme family, catalyzing the covalent attachment of ubiquitin to substrate proteins[5][6]. It is involved in both canonical and noncanonical ubiquitylation, uniquely capable of attaching ubiquitin to not only lysine but also serine, threonine, cysteine, and even complex sugars or glucose residues[1]. UBE2Q1 contains an extended N-terminal domain and an RWD domain, and can function independently of E3 ligases for certain noncanonical substrates. It shows substrate specificity and is implicated in hormonal regulation and potentially tumor biology, although detailed clinical targeting information and drugs are currently lacking[6][1].

Other names
NICE5UBE2QPRO3094NICE-5E2 ubiquitin-conjugating enzyme Q1Protein NICE-5Ubiquitin carrier protein Q1Ubiquitin-protein ligase Q1GTAPgalactosyl transferase-associated proteinubiquitin conjugating enzyme E2Q family member 1ubiquitin-conjugating enzyme E2Q (putative) 1
02

Mechanism of action

Drugs (if developed) would likely act as inhibitors or modulators of protein ubiquitin-conjugation activity.

03

Biological functions

Protein ubiquitylationProteasomal protein degradationRegulation of hormonal homeostasis (suggested in females)
04

Disease associations

Cancer (altered expression in tumors reported in literature outside main search results)Other (potential roles in cellular stress response via protein turnover)
05

Safety considerations

Broad inhibition may disrupt protein homeostasis, potentially affecting multiple cellular processes.

Beyond the preview

Go deeper on Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call